

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/58, 9/10	A1	(11) International Publication Number: WO 98/24450 (43) International Publication Date: 11 June 1998 (11.06.98)
(21) International Application Number: PCT/SE97/01998 (22) International Filing Date: 28 November 1997 (28.11.97) (30) Priority Data: 9604486--2 5 December 1996 (05.12.96) SE 08/846,960 29 April 1997 (29.04.97) US (71) Applicant (for all designated States except US): ASTRA AKTIEBOLAG (publ) [SE/SE]; S-151 85 Södertälje (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): NILSSON, Hans [SE/SE]; Hjalmar Gullbergs Väg 24, S-224 66 Lund (SE). SANTES- SON, Gordon [SE/SE]; Anemongatan 6, S-242 34 Hörby (SE). (74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: NOVEL FORMULATION (57) Abstract A new metered unit dose comprising 40 µg or less of budesonide is disclosed as well as a formulation thereof and the use thereof for the treatment of conditions in the nose.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NOVEL FORMULATION

Field of the Invention

- 5 The present invention relates to a new unit dose of budesonide, a formulation thereof, and its use for the treatment of conditions of the nose.

Background of the Invention

- Glucocorticosteroids are widely used for the treatment of seasonal allergic as well as
10 perennial rhinitis. Intranasal glucocorticosteroids reduce inflammation of the nasal mucosa including edema. In addition, they are known to suppress the recruitment of polymorpho-nuclear and mononuclear cells, cytokine production, and, during maintenance treatment, both early and late-phase nasal reactions.

- 15 One of the glucocorticosteroids known for intranasal use is budesonide, $16\alpha,17\alpha$ -butylidenedioxy- $11\beta,21$ -dihydroxypregna- $1,4$ -diene- $3,20$ -dione.

- Initially solid budesonide was used in pressurized metered dose inhaler (pMDI) preparations for intranasal administration, suitably dispensed from a specially adapted nasal inhaler. A
20 recommended maximum daily metered dose of budesonide has been $400\text{ }\mu\text{g}$. Later on a nasal spray preparation for delivery from a spray device was prepared, containing budesonide in the form of an aqueous suspension. The same maximum daily metered dose as for the pMDI preparation was recommended. A third formulation is a dry powder formulation.

- 25 Both the nasal pMDI inhaler device and the aqueous nasal spray device are constructed to dispense a defined unit dose at each actuation. For example, a metered unit dose of $50\text{ }\mu\text{g}$ has a recommended administration regime of one dose per nostril, four times daily, yielding a total of eight $50\text{ }\mu\text{g}$ metered doses per day. Alternatively, a metered unit dose of $100\text{ }\mu\text{g}$

would provide the same total metered daily dose (400 µg) if administered to each nostril twice daily, for a total of four 100 µg metered doses per day.

We have now surprisingly found that a lower metered unit dose of budesonide than that previously used can be administered safely and effectively to the nose.

Disclosure of the invention

According to the invention we provide a metered unit dose of a therapeutic composition comprising budesonide in therapeutically effective amount that is less than about 40µg, said composition being suitable for nasal administration to a mammal in a single dose.

Preferably, the metered unit dose comprises from about 16 to about 40 µg of budesonide. In a preferred embodiment of the invention, the metered unit dose comprises about 32 µg of budesonide.

With this new lower metered unit dose, it is possible for the patient to take a lower metered daily dose, while still maintaining efficacy. The new lower unit dose is also convenient for the patient. Surprisingly, metered daily doses of 256 µg and 400 µg, delivered by nasal spray, were found to be equally efficacious. A metered daily dose of 256 µg can be obtained with a metered unit dose of 32 µg budesonide, dispensed 8 times daily (two doses in each nostril, twice a day). Once the patient has achieved relief using a daily dose of 256 µg (this may be achieved in from 12 hours to 7 days from the initiation of treatment depending on the patient and the severity of the condition) the daily dose may be reduced to 128 µg, preferably administered as two doses in each nostril once a day and preferably in the morning. In certain circumstances the daily dose may be reduced even further, e.g. to 64µg, by administering one dose to each nostril once a day, again preferably in the morning.

A suitable pharmaceutical formulation of budesonide is a suspension of micronised budesonide in an aqueous vehicle.

Thus, the invention also comprises a unit dose, and preferably a metered unit dose, of a therapeutic composition comprising a therapeutically effective amount of budesonide that is less than about 40 μ g, wherein the budesonide is in the form of finely divided particles and is suspended in an aqueous medium, said composition being suitable for administration to a mammal in a single dose..

Preferably, the unit dose formulation comprises from about 16 to about 40 μ g of budesonide. In a most preferred embodiment of the formulation, the amount of budesonide is about 32 μ g.

In a further aspect the invention comprises a suspension, preferably an aqueous suspension, comprising from about 0.6 to about 0.7 mg/ml (i.e. from about 0.06 to about 0.07% w/w) of budesonide.

In yet a further aspect the invention comprises a method of treating conditions of the nose of mammals by administering thereto a metered unit dose of 40 μ g or less of budesonide.

Conditions that can be treated according to the invention include

- seasonal allergic rhinitis, i.e. pollinosis caused by pollens from ragweed, birch, grass, cedar or other plants
- perennial allergic rhinitis caused by e.g. dust mites (*Dermatophagoides pteronyssinus* and *D. farinae*), cockroaches and mammals such as cats, dogs and horses
- perennial non-allergic rhinitis
- nasal polyps, as well as prevention of post surgical nasal polyps
- chronic sinusitis
- recurrent sinusitis.

In order to form a stable suspension with a minimal tendency to agglomerate or form a sediment, a thickening agent may be included in the formulation. Examples of suitable thickening agents are microcrystalline cellulose, sodium carboxymethylcellulose, xanthan

gum, carbomer, guar gum and hydroxypropyl cellulose. The thickening agent may be present at about 0.1 to 3.0% w/w of the formulation. Preferably microcrystalline cellulose and sodium carboxymethyl cellulose are present at about 0.5 to 2.5%, xanthan gum at about 0.3 to 3%, carbomer at about 0.1 to 2%, guar gum at about 0.3 to 2% and hydroxypropyl methyl cellulose at about 0.5 to 3.0%, w/w of the formulation.

Agents which make the suspension isotonic may be added. Examples are dextrose, glycerin, mannitol, sodium chloride and potassium chloride.

To obtain an efficient dispersion of the budesonide particles in the suspension, a surfactant may be used. Examples of suitable surfactants are Polysorbate 80 (Tween 80) as well as other polyoxyethylene sorbitan fatty acid esters, poloxamers, polyoxyethylene alkyl ethers and polyoxyethylene castor oil derivatives. The surfactant may be present at about 0.005 to 2% w/w of the formulation. We prefer the polyoxyethylene sorbitan fatty acid esters to be present at about 0.005 to 0.5%, poloxamers at about 0.01 to 2%, and polyoxyethylene alkyl ethers or the polyoxyethylene castor oil derivatives at about 0.01 to 1.0%, w/w of the formulation.

We also prefer the formulation to contain a suitable chelating agent, e.g. disodium edetate (EDTA). The chelating agent may be present at about 0.005 to 0.1% w/w of the formulation.

A preservative agent may be added to protect the formulation from microbial contamination. Examples of suitable preservatives are benzalkonium chloride, methylparaben, propylparaben, potassium sorbate and sodium benzoate. The preservative may be present at about 0.002 to 0.5% w/w of the formulation. Preferably benzalkonium chloride is present at about 0.002 to 0.02%, methylparaben at about 0.05 to 0.25%, propylparaben at about 0.01 to 0.2%, potassium sorbate at about 0.5 to 0.2%, and sodium benzoate at about 0.1 to 0.5%, w/w of the formulation.

The pH of the suspension may be adjusted as required. Examples of suitable pH regulating agents are strong mineral acids, e.g. hydrochloric acid. Alternatively, the pH of the system can be adjusted by balancing the acid and salt forms of preservative and chelating agent. We prefer the formulation to have a pH in the range 3.5 to 5.0, more preferably 4.0 to 4.8, and most preferably from about 4.2 to 4.6.

The suspension medium is made essentially of purified water (as describe in the European Pharmacopoeia and the United States Pharmacopoeia), e.g. water for injection.

10 In the suspension the active constituent budesonide is present as small particles, where at least 90% of the small particles have a mass equivalent sphere diameter of less than 20 μ m, preferably at least 80% less than 10 μ m and most preferably at least 80% less than 7 μ m.

The new unit dose can suitably be dispensed from the above mentioned specially adapted nasal inhaler or spray device. Other means for administration include a simple drop pipette or a rhinyl. Pre-compression metered-dose spray pumps with dose volumes from 25 μ l to 150 μ l can be used, whereby the concentration of budesonide in the suspension is adjusted to give the desired unit dose of budesonide. Monospray or a bispray pump can be used; for the latter, the recommended unit dose is sequentially delivered into each nostril, for a total metered dose per administration of less than 80 μ g budesonide.

According to a further feature of the invention we also provide a therapeutic method of treating or preventing conditions of the upper respiratory tract, the method comprising metering into a nostril of a mammal a unit dose of budesonide, wherein said metered unit dose comprises budesonide in a therapeutically effective amount that is less than about 40 μ g.

The metered amount of budesonide is preferably less than about 320 μ g per day, delivered as 8 or more unit doses each dose comprising budesonide in an amount that is less than about 40 μ g.

According to a yet further feature of the invention we provide a container containing budesonide and adapted to deliver a unit dose or a formulation according to the invention.

5 The invention will now be described more in detail in the following non-limiting examples.

EXAMPLE 1

A unit dose comprising a suspension of 32 µg budesonide in water was prepared by mixing the following ingredients:

10

Ingredient	(mg)
Budesonide, micronised	0.032
Microcrystalline cellulose and carboxymethylcellulose Sodium (Avicel)	0.625
Dextrose, anhydrous	2.375
Polysorbate 80	0.008
Edetate disodium	0.005
Potassium sorbate	0.060
Hydrochloric acid	to pH 4.5
Purified water	to 50 µl (approx. 47.9 mg added)

EXAMPLE 2

A 200 litre bulk suspension, which corresponds to approximately 23,000 containers with 120 doses (32 µg/dose) of budesonide each, was prepared by mixing the following

15 ingredients:

Ingredient	Amount (kg)
Budesonide, micronised	0.128
Microcrystalline cellulose and carboxymethylcellulose Sodium (Avicel)	2.500
Dextrose, anhydrous	9.500
Polysorbate 80	0.032
Edetate disodium	0.020
Potassium sorbate	0.240
Hydrochloric acid	to pH 4.5
Purified water	to 204.2

CLAIMS

1. A metered unit dose of a therapeutic composition comprising budesonide in a
5 therapeutically effective amount that is less than about 40 μ g, said composition being
suitable for nasal administration to a mammal in a single dose.
2. A unit dose according to claim 1, comprising from about 16 to about 40 μ g of
budesonide.
- 10 3. A unit dose according to claim 1, comprising about 32 μ g budesonide.
4. A unit dose according to anyone of the preceding claims wherein the budesonide is in
the form of finely divided particles and is suspended in an aqueous medium.
- 15 5. A formulation comprising a suspension of about 0.6 to about 0.7 mg/ml of finely divided
budesonide in water.
6. A unit dose according to any one of claims 1 to 4 or a formulation according to claim 5,
20 further comprising a pharmaceutically acceptable thickening agent, isotonicity agent,
surfactant, chelating agent, or preservative.
7. A unit dose according to any one of claims 1 to 4 and 6, or a formulation according to
claim 5 or 6, wherein the mass equivalent sphere diameter of the budesonide is 10 μ m or
25 less.
8. Use of a unit dose or of a formulation according to any one of the preceding claims in
the preparation of a pharmaceutical for treating or preventing conditions of the upper
respiratory tract by nasal administration.

9. Use according to claim 8, in which the condition is seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, chronic sinusitis, recurrent sinusitis or nasal polyps.
- 5 10. Use according to claim 8 or 9, wherein the budesonide is to be metered into the nose of a mammal at a dose of 320 μg , or less, per day, delivered as 8 or more unit doses, wherein each unit dose comprises budesonide in an metered amount that is less than 40 μg .
- 10 11. Use according to claim 10, wherein the amount of budesonide is about 256 μg per day.
12. A container containing budesonide and adapted to deliver a unit dose according to any one of claims 1 to 4, or 6 or 7 or a formulation according to any one of claims 5 to 7.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 97/01998

A. CLASSIFICATION OF SUBJECT MATTER		
IPC6: A61K 31/58, A61K 9/10 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC6: A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
WPI, CLAIMS, EMBASE, MEDLINE, CAPLUS		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 9701341 A1 (MCNEIL-PPC, INC.), 16 January 1997 (16.01.97), page 4, line 34 - page 5, line 5; page 7, line 12 - page 8, line 20 --	1-12
X	US 3992534 A (RALPH LENNART BRATTSAND ET AL), 16 November 1976 (16.11.76), column 15, line 11 - line 31, claims --	1-12
A	STN International, File CAPLUS, CAPLUS accession no. 1995:932729, Pedersen, Soren et al: "Budesonide treatment of moderate and severe asthma in children: A dose - response study"; & J. Allergy Clin. Immunol. (1995), 95(1, Pt. 1), 29-33 --	1-12
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
26 March 1998		30 -03- 1998
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer Anneli Jönsson Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 97/01998

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>Dialog Information Services, File 155, MEDLINE, Dialog accession no. 07274454, Medline accession no. 93064921, Arnon, S et al: "Delivery of micro- nized budesonide suspension by metered dose inhaler and jet nebulizer into a neonatal ventilator circuit"; & Pediatr Pulmonol (UNITED STATES) Jul 1992, 13 (3) p172-5</p> <p>-- -----</p>	1-12

INTERNATIONAL SEARCH REPORT

Information on patent family members

02/03/98

International application No.

PCT/SE 97/01998

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	9701341	A1	16/01/97	AU	6290396 A	30/01/97
<hr/>						
US	3992534	A	16/11/76	AU	5525273 A	07/11/74
				BE	799728 A	17/09/73
				CA	1003402 A	11/01/77
				CY	1012 A	23/11/79
				DE	2323216 A,C	29/11/73
				DK	133249 B,C	12/04/76
				FR	2185406 A,B	04/01/74
				GB	1428416 A	17/03/76
				HK	49079 A	27/07/79
				JP	975395 C	19/10/79
				JP	49041379 A	18/04/74
				JP	54007794 B	10/04/79
				KE	2969 A	20/07/79
				NL	175917 B,C	16/08/84
				NL	7306979 A	21/11/73
				SE	378110 B,C	18/08/75
				US	3928326 A	23/12/75
				US	3996359 A	07/12/76
				ZA	7302956 A	24/04/74
<hr/>						